8-K: Nutex Health Reports Strong 2024 Growth Amid Restatement

Nutex Health Inc. announced significantly improved restated financial results for 2024, reporting substantial revenue growth and a shift from net loss to net income, despite minor non-cash adjustments.

Summary

• Nutex Health Inc. reported restated financial results for the full year and fourth quarter ended December 31, 2024.
• Total revenue for 2024 increased by 93.8% to $479.9 million, up from $247.6 million in 2023.
• The company achieved a net income attributable to Nutex Health Inc. of $52.1 million for 2024, a significant turnaround from a net loss of $45.8 million in 2023.
• Diluted income per share was $9.69 for 2024, compared to a loss per share of $10.39 in 2023.
• Adjusted EBITDA surged by 1046.1% to $124.1 million in 2024, from $10.8 million in 2023.
• Net cash from operating activities for 2024 was $23.2 million.
• The restatement involved non-cash adjustments, including reclassifying $16.4 million in stock-based compensation obligations from equity to liabilities, $3.5 million in related-party accounts payable from liabilities to equity, and $2.9 million of restricted balances from cash to short-term investments, along with an increase of $0.5 million in accrued income tax expense.
• These restatement adjustments resulted in a $13.4 million increase in liabilities and a corresponding decrease in equity, with a nominal $0.5 million decrease in net income and a $0.02 decrease in diluted EPS to $9.69.
• The restatement had no material effect on key metrics such as revenue, liquidity, debt, operating cash flow, adjusted EBITDA, or patient visits.
• The Hospital Division saw total visits increase by 16.9% to 168,388 for 2024, with mature hospital visits up by 6.5%.

Sentiment

Score: 8

Explanation: The filing presents overwhelmingly positive financial results, including significant revenue growth, a strong turnaround to profitability, and robust Adjusted EBITDA. While a restatement occurred, its impact was nominal and non-cash, not detracting from the underlying operational strength. Management expresses high confidence and plans a stock repurchase program, further boosting sentiment.

Positives

• Total revenue for 2024 increased by 93.8% to $479.9 million, demonstrating strong top-line growth.
• Achieved a net income of $52.1 million in 2024, a significant improvement from a $45.8 million net loss in 2023.
• Diluted income per share turned positive to $9.69 in 2024, from a loss of $10.39 per share in 2023.
• Adjusted EBITDA saw a substantial increase of 1046.1% to $124.1 million in 2024, indicating improved operational efficiency.
• Gross profit increased by 464.4% year-over-year, reaching $196.3 million in 2024.
• Net cash from operating activities was positive at $23.2 million for 2024, reflecting healthy cash generation.
• The company reported a record high cash balance of $40.6 million as of December 31, 2024.
• Hospital Division visits increased by 16.9% to 168,388 for the year, showing growing patient engagement.
• Revenue from mature hospitals increased by 56.6% in 2024 compared to 2023, indicating sustained performance from established facilities.

Negatives

• The company's financial statements for 2024 required restatement due to classification errors, although the impact on net income and key operational metrics was nominal and non-cash.
• Diluted earnings per share decreased by $0.02 from $9.71 to $9.69 as a result of the restatement adjustments.

Risks

• Ability to successfully execute the company's growth strategy.
• Changes in laws or regulations, including the interim final and final rules implemented under the No Surprises Act.
• General economic conditions affecting healthcare demand and operations.
• Dependence on key management personnel.
• Potential for dilution to stockholders from future equity issuances.
• Lack of capital for expansion or operational needs.
• Effects of rapid growth on the company's infrastructure and management's ability to respond effectively.
• Impact of newly developing technologies in the healthcare sector.
• Ability to compete effectively in the healthcare market.
• Conflicts of interest that may arise in related party transactions.
• Regulatory matters and compliance requirements.
• Protection of proprietary technology and intellectual property.
• Lack of established industry standards in certain areas of operation.
• Effects of competition from other healthcare providers.
• Ability to obtain future financing on favorable terms.

Future Outlook

The company plans to execute on its growth plan for 2025, with the arbitration process becoming an ongoing part of its revenue cycle management. Management believes its shares are undervalued and intends to execute a previously announced stock repurchase program opportunistically to drive increased earnings per share and total shareholder return.

Management Comments

• "We are pleased to report 93.8% revenue growth, Adjusted EBITDA attributable to Nutex Health of $124.1 million, a 464.4% increase in gross profit and a record high cash balance of $40.6 million, all on a restated basis and materially the same as originally reported, highlighting the Company's continued financial strength and solid fundamentals as we execute on our growth plan for 2025." Jon Bates, Chief Financial Officer.
• "The arbitration process that we started in 2024 is now an ongoing part of our revenue cycle management process. In addition, the Company believes its shares are currently undervalued, and our previously announced stock repurchase program underscores our confidence in the long-term prospects of Nutex Health. We anticipate executing this program opportunistically with the goal of driving increased earnings per share and total shareholder return." Tom Vo, M.D., MBA, Chairman and Chief Executive Officer.

Industry Context

Nutex Health operates in the integrated healthcare delivery system, focusing on micro-hospitals, HOPDs, and population health management. The strong revenue growth and shift to profitability suggest effective execution within a dynamic healthcare landscape, potentially benefiting from increased demand for localized, accessible care models. The mention of the 'No Surprises Act' indicates the ongoing regulatory challenges and adaptations required in the U.S. healthcare industry.

Comparison to Industry Standards

• NA

Corporate Governance

Legal Proceedings

• The arbitration process that started in 2024 is now an ongoing part of the company's revenue cycle management process.

Related Party Transactions

• Reclassified related-party accounts payable balances of $3.5 million from liabilities to equity as part of the restatement adjustments.
• Conflicts of interest in related party transactions are listed as a potential risk factor.

Stakeholder Impact

• Shareholders: Positive impact due to significant increase in net income and diluted EPS, strong revenue growth, and management's confidence leading to a planned stock repurchase program. The restatement's nominal impact is unlikely to cause significant concern.
• Employees: Continued growth and expansion of operations (24 facilities in 11 states) suggest job stability and potential for growth.
• Customers (Patients): Increased hospital visits and expansion of facilities indicate growing service delivery and access to care.
• Creditors: Improved financial health, positive operating cash flow, and increased cash balance enhance the company's ability to meet its obligations.
• Suppliers: Increased operational activity and revenue growth may lead to increased demand for supplies and services.

Next Steps

• Execute on the company's growth plan for 2025.
• Continue the arbitration process as an ongoing part of revenue cycle management.
• Opportunistically execute the previously announced stock repurchase program to drive increased earnings per share and total shareholder return.
• Refer to the Amended Annual Report on Form 10-K/A for more detailed restated financial results.

Key Dates

Recommendation

Nutex Health Inc. has demonstrated exceptional financial performance in 2024, marked by a near doubling of revenue, a significant turnaround from a substantial net loss to a healthy net income, and an exponential increase in Adjusted EBITDA. The restatement, while notable, had a minimal, non-cash impact on the core financial results and does not detract from the underlying operational strength. Management's confidence, evidenced by the belief that shares are undervalued and the commitment to a stock repurchase program, signals strong internal conviction. The company's growth trajectory in the integrated healthcare sector, coupled with robust cash generation, positions it favorably for future appreciation. The current valuation, especially in light of the strong earnings turnaround, appears attractive for long-term investors.

Keywords

Healthcare, Micro-hospitals, Hospital Outpatient Departments, Population Health Management, Financial Results, Restatement, EBITDA, Revenue Growth, Net Income, NASDAQ: NUTX